Single-cell transcriptomics reveals immune suppression and cell states predictive of patient outcomes in rhabdomyosarcoma

被引:0
作者
Jeff DeMartino
Michael T. Meister
Lindy L. Visser
Mariël Brok
Marian J. A. Groot Koerkamp
Amber K. L. Wezenaar
Laura S. Hiemcke-Jiwa
Terezinha de Souza
Johannes H. M. Merks
Anne C. Rios
Frank C. P. Holstege
Thanasis Margaritis
Jarno Drost
机构
[1] Princess Máxima Center for Pediatric Oncology,Department of Pathology
[2] Oncode Institute,Center for Molecular Medicine
[3] University Medical Center Utrecht,undefined
[4] UMC Utrecht and Utrecht University,undefined
来源
Nature Communications | / 14卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Paediatric rhabdomyosarcoma (RMS) is a soft tissue malignancy of mesenchymal origin that is thought to arise as a consequence of derailed myogenic differentiation. Despite intensive treatment regimens, the prognosis for high-risk patients remains dismal. The cellular differentiation states underlying RMS and how these relate to patient outcomes remain largely elusive. Here, we use single-cell mRNA sequencing to generate a transcriptomic atlas of RMS. Analysis of the RMS tumour niche reveals evidence of an immunosuppressive microenvironment. We also identify a putative interaction between NECTIN3 and TIGIT, specific to the more aggressive fusion-positive (FP) RMS subtype, as a potential cause of tumour-induced T-cell dysfunction. In malignant RMS cells, we define transcriptional programs reflective of normal myogenic differentiation and show that these cellular differentiation states are predictive of patient outcomes in both FP RMS and the less aggressive fusion-negative subtype. Our study reveals the potential of therapies targeting the immune microenvironment of RMS and suggests that assessing tumour differentiation states may enable a more refined risk stratification.
引用
收藏
相关论文
共 102 条
[1]  
Li J(2008)Cancer incidence among children and adolescents in the United States, 2001-2003 Pediatrics 121 e1470-e1477
[2]  
Thompson TD(2003)Myogenin and MyoD1 expression in paediatric rhabdomyosarcomas J. Clin. Pathol. 56 412-416
[3]  
Miller JW(1988)Ultrastructural organization of cell characteristics relevant to diagnosis in rhabdomyosarcomas Zentralblatt f.ür. Allg. Pathologie Pathologische Anat. 134 449-466
[4]  
Pollack LA(2018)Hedgehog Pathway Drives Fusion-Negative Rhabdomyosarcoma Initiated From Non-myogenic Endothelial Progenitors Cancer Cell 33 108-124.e5
[5]  
Stewart SL(2008)Prognostic factors in metastatic rhabdomyosarcomas: Results of a pooled analysis from United States and European Cooperative Groups J. Clin. Oncol. 26 2384-2389
[6]  
Sebire NJ(2012)PAX3/FOXO1 fusion gene status is the key prognostic molecular marker in rhabdomyosarcoma and significantly improves current risk stratification J. Clin. Oncol. 30 1670-1677
[7]  
Malone M(2010)Fusion gene-negative alveolar rhabdomyosarcoma is clinically and molecularly indistinguishable from embryonal rhabdomyosarcoma J. Clin. Oncol. 28 2151-2158
[8]  
Stiller D(2007)The role of Pax genes in the development of tissues and organs: Pax3 and Pax7 regulate muscle progenitor cell functions Annu. Rev. Cell Dev. Biol. 23 645-673
[9]  
Holzhausen HJ(1993)Fusion of a fork head domain gene to PAX3 in the solid tumour alveolar rhabdomyosarcoma Nat. Genet. 5 230-235
[10]  
Drummond CJ(1996)In vivo amplification of the PAX3-FKHR and PAX7-FKHR fusion genes in alveolar rhabdomyosarcoma Hum. Mol. Genet. 5 15-21